A Phase I/II Trial of WT1-Specific TCR Gene Therapy for Patients with Acute Myeloid Leukemia and Active Disease Post-Allogeneic Hematopoietic Cell Transplantation: Skewing Towards NK-Like Phenotype Impairs T Cell Function and Persistence

By
Jamie Kang
-
0
3204
In this Phase I/II clinical trial, scientists evaluated safety, persistence, and efficacy of Epstein-Barr virus- or Cytomegalovirus-specific Wilms Tumor Antigen 1-specific T-cell receptor in 15 patients with active AML post-HCT.
[Nature Communications]
Full Article